Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites.
We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (…

We describe the landscape of somatic genomic alterations of 66 chromophobe renal cell
carcinomas (ChRCCs) on the basis of multidimensional and comprehensive characterization, …

Background Tumor-infiltrating immune cells have been linked to prognosis and response to
immunotherapy; however, the levels of distinct immune cell subsets and the signals that …

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers
with different genetic drivers, clinical courses, and therapeutic responses. The current …

Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade. …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

To elucidate the deregulated functional modules that drive clear cell renal cell carcinoma (ccRCC),
we performed comprehensive genomic, epigenomic, transcriptomic, proteomic, and …

10.7554/eLife.10769.001 Mutations, deletions, and changes in copy number of mitochondrial
DNA (mtDNA), are observed throughout cancers. Here, we survey mtDNA copy number …